The New Paper

January 29, 2021

Johnson and Johnson and Novavax announce coronavirus vaccine trial results

Johnson & Johnson and Novavax announced results from late-stage clinical trials for their respective coronavirus vaccines. J&J found its vaccine to be 66% effective overall (including 72% in the US and 57% in South Africa), while Novavax found its vaccine to be 89% effective overall (including 49% in South Africa). Both companies were recipients of funding through “Operation Warp Speed” last year, and the US government has secured access to 100M doses from each firm.

Extra: J&J’s vaccine notably uses a single dose, compared to previously approved vaccines from Pfizer and Moderna that require two doses.
This story is from the January 29, 2021 edition of The New Paper – a clear, concise daily briefing that makes fact-first news easy to consume. Try it today.